1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
EVE Health Group Limited

EVE Health Group Limited

AASX:EVE
0.02
AUD
+0.00
(+7.14%)
-0.01EPS
6.69MMarket Cap
EVE Health Group Limited
ASX:EVE
(Australian Securities Exchange)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
AUD
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.02
0.02
0.02
0.02
0.02
0.01
- -
Revenue per Share
1.82
-0.43
-1.32
-0.02
-0.41
-0.05
-0.04
-0.03
-0.04
-0.03
-0.03
-0.05
-0.02
-0.01
-0.01
-0.01
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.13
1.75
0.61
0.46
0.14
0.05
0.06
0.11
0.08
0.12
0.09
0.05
0.03
0.01
0.03
0.01
Book Value per Share
2.13
1.75
0.61
0.46
0.14
0.05
0.06
0.11
0.07
0.11
0.08
0.05
0.03
0.01
- -
- -
Tangible Book Value per Share
12
12
13
16
18
24
37
56
69
94
115
100
130
132
137
292
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
2
2
3
2
2
2
2
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
-8,597.54
-109.03
-113.2
-125.2
-180.7
-100.84
-72.34
-82.33
-164.81
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
21
-5
-17
- -
-7
-1
-1
-2
-3
-2
-4
-5
-3
-2
-2
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
-9,944.97
-165.62
-103.86
-129.62
-224.71
-131.74
-89.09
-91.08
-163.97
Profit Margin (%)
7
2
1
1
- -
- -
- -
4
- -
6
4
2
4
1
1
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
- -
LT Debt
26
23
8
8
3
2
3
7
6
13
10
7
4
1
4
4
Total Equity
-16.79
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
83.57
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
112.11
-21.36
-111.73
-4.75
-136.97
-50.27
-61.27
-37.01
-40.01
-25.48
-31.32
-62.75
-55.66
-71.43
-66.16
-50.42
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.25%
11.67%
11.1%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
11.38%
-6.04%
19.67%
Sales/Revenue/Turnover
- -
-15.57%
-33.53%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2
2025
- -
- -
2
2026
- -
- -
1

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
-0.01
2026
- -
- -
-0.01

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
EVE Health Group Limited, alongside its associated entities, operates as an Australian innovator in the health, nutrition, and wellness sectors, extending its reach across Australia, New Zealand, the Asia Pacific, and North America. The company is at the forefront of developing and commercialising fast-acting pharmaceutical solutions, leveraging proprietary solubility-enhancing delivery technologies. This includes Dyspro™, a non-hormonal gummy designed to alleviate menstrual pain and endometriosis symptoms, which commenced its Australian rollout in September 2025. Additionally, EVE is preparing for the Australian launch of Libbo™ in December 2025, an oral strip formulated for rapid relief of erectile dysfunction. Beyond pharmaceuticals, the group maintains a portfolio of natural health and wellness offerings. This encompasses organic raw honey and probiotic concentrates, alongside a range of digestive health supplements, primarily under the Meluka Australia brand. They also distribute certified organic tea tree oils and other Australian botanical oils through Jenbrook Australia. The company’s unique value stems from its nanoemulsion platform, which facilitates quicker absorption and enhanced bioavailability for its products, aiming to deliver patient benefits with greater speed. Recent developments include a significant capital raise and the establishment of telehealth partnerships to support its expanding product lines. Formerly known as EVE Investments Limited, EVE Health Group Limited was established in 2003 and is headquartered in Subiaco, Australia.